[Surgical treatment of hepatocellular carcinoma in cirrhosis].
Despite the recent development of percutaneous ethanol injection and liver transplantation, liver resection remains the reference treatment for hepatocellular carcinoma (HCC). The two drawbacks of this treatment are the risk associated with surgery and the high recurrence rate. Both are related to the almost constant presence of a chronic underlying liver disease. The risk of surgery has decreased significantly over the past 10 years and is currently less than 10%, even after a major hepatectomy, provided that cirrhosis is compensated (Child A) and that there is no superimposed chronic active hepatitis. Recurrence is usually related to de novo carcinogenesis Adjuvant and neoadjuvant therapies have no clearly demonstrated benefit. However, postoperative follow-up is mandatory as some recurrences are arnenable to local treatment, particularly rehepatectomy that has an efficacy comparable to that of first hepatectomy.
Farges
O
O
Service de Chirurgie Digestive et de Transplantation Hépatique, Université Paris VII, Hôpital Beaujon, Clichy.
Belghiti
J
J
D000206:Actuarial Analysis; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000601:surgery*; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D015994:Incidence; D008103:Liver Cirrhosis / Q000150:complications*; D008113:Liver Neoplasms / Q000209:etiology / Q000601:surgery*; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D012086:Reoperation; D016896:Treatment Outcome